Echinacea: benefits, dosage, contraindications

Mis à jour le

Echinacea (the echinaceas, a term derived from the Greek echino, 'spine', because of the spiny central disc of the flower) is a genus of plants in the Asteraceae family, native to North America, which is now also cultivated in Europe. Echinacea is a perennial plant with erect stems measuring 60 to 120 cm in height. It can be likened to sunflowers and daisies. Echinacea was used in traditional medicine by the Native Americans of the Great Plains region to treat various ailments such as external wounds or snakebites. It was later adopted by settlers, who began using it as an anti-infective medicine from 1800 onward. Introduced into Europe in 1895, echinacea was listed among plant-based medicines in the United States and produced by pharmaceutical companies, before being supplanted by the arrival of antibiotics on the market in 1940. The parts of the three Echinacea species used therapeutically (Echinacea purpurea, Echinacea angustifolia and Echinacea pallida) are the aerial parts and the roots. Echinacea contains polysaccharides, alkylamides, phenolic derivatives (derivatives of caffeic acid, chlorogenic acid, chicoric acid, echinacoside), essential oils, as well as a range of vitamins, minerals, fatty acids, resins, glycoproteins and sterols. Echinacea is used orally as an immunostimulant to combat various infections, to treat and prevent the common cold, cough, the flu and other upper respiratory tract infections.

Scientific name(s)

Echinacea angustifolia, Echinacea purpurea, Brauneria angustifolia, Echinacea pallida

Family or group: 

Plants

Active ingredients:

Echinacoside

Cichoric acid

Caffeic acid

Alkylamides

Cynarine


Indications

Scoring methodology

EFSA approval.

Several randomized, double-blind, controlled clinical trials (> 2), including a significant number of patients (>100), with consistently positive conclusions for the indication.
Several randomized, double-blind, controlled clinical trials (> 2), including a significant number of patients (>100), with positive conclusions for the indication.
One or more randomized studies, or several cohorts or epidemiological studies, with positive conclusions for the indication.
Clinical studies exist but are uncontrolled, with conclusions that may be positive or conflicting.
No clinical studies to date that can demonstrate the indication.


Immune support
✪✪✪✪

Echinacea exerts an immunostimulant effect. Its effect on the immune system has been demonstrated in vitro and in vivo. In a randomized, double-blind, placebo-controlled trial, the total daily number of common cold symptoms was lower with echinacea than with placebo, and the difference was statistically significant after the third day. An increase in total leukocyte, monocyte, and neutrophil counts—but not lymphocytes—and an increase in neutrophil respiratory burst capacity were also observed, while erythrocyte superoxide dismutase units decreased during echinacea treatment.

Posologie

posologieOral: root, aerial parts

posologie1500 - 2400 mg

duration1 - month

populationAdults

formulationstandardized extract, dry extract


Common cold
✪✪✪✪

The reduction in the rate of ENT infections observed with echinacea as a daily supplement appears to be very effective in some cases, but is subject to a high degree of variability. Meta-analyses show a modest reduction in the risk of developing a common cold when taking various echinacea products. A large clinical study conducted with Echinaforce (A. Vogel) shows that adults who take 0.9 ml three times a day (providing 2,400 mg of echinacea per day) for 4 months, or 0.9 ml five times a day (4 g of echinacea per day) at the first sign of a cold, have fewer episodes and shorter duration of common cold than those who take a placebo. Overall, the data confirm a low-to-moderate efficacy. The EMA lists echinacea as an herbal medicinal product for the prevention and the short-term treatment of the common cold.

Posologie

posologieOral use: root, aerial parts

posologie900 - 4000 mg

duration4 - months

formulationstandardized extract, dry extract

Echinacea for treating the common cold: a randomized trial.
Echinacea purpurea for prevention of experimental rhinovirus colds.
Randomized, double-blind, placebo-controlled trial of echinacea supplementation in air travelers.
Echinacea for the prevention and treatment of upper respiratory tract infections: A systematic review and meta-analysis.
Echinacea in the prevention of induced rhinovirus colds: a meta-analysis.
Use of a standardized extract from Echinacea angustifolia (Polinacea) for the prevention of respiratory tract infections.
Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Echinacea for preventing and treating the common cold.
Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial.
Echinacea purpurea and mucosal immunity
European Union herbal monograph on Echinacea purpurea (L.) Moench, radix
Echinaforce and other Echinacea fresh plant preparations in the treatment of the common cold. A randomized, placebo-controlled, double-blind clinical trial.
An evaluation of Echinacea angustifolia in experimental rhinovirus infections.
A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections.
Evaluation of Echinacea for the prevention and treatment of the common cold: a meta-analysis
Efficacy and safety of Echinacea in treating upper respiratory tract infections in children: a randomized controlled trial.
Ineffectiveness of Echinacea for prevention of experimental rhinovirus colds.
Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial.

Respiratory infections, Flu
✪✪✪✪✪

Echinacea may have antiviral activity against influenza virus, rhinoviruses, and herpes simplex viruses (HSV-1 and HSV-2). Preliminary research using viruses from nasal secretions suggests that Echinacea purpurea may inhibit enveloped viruses such as coronaviruses, influenza viruses, parainfluenza viruses, respiratory syncytial viruses, and metapneumoviruses. Clinically, a recent Cochrane systematic review indicates that the efficacy of echinacea may be superior to placebo for reducing the incidence of influenza, suggesting its potential usefulness as a preventive intervention. Another large study conducted in adults with respiratory infections shows that taking a daily 5-day combination containing 1100 to 2200 mg of echinacea, zinc, and vitamin C shortens recovery time; however, it had no major effect on symptom severity compared with placebo.

Posologie

posologieOral: root, aerial parts

posologie900 - 2200 mg

duration5 days

populationAdults, Children

formulationstandardized extract, dry extract


Synergies


Pharyngitis
✪✪✪✪✪

Thanks to its antiviral and antibacterial action, Echinacea may be used in cases of pharyngitis and even bronchitis. An observational study examined the efficacy of an Echinacea and Sage lozenge in the treatment of pharyngitis. The study showed a significant reduction in viral load and symptoms, such as sore throat. However, there was no control group, which limits the validity of these results. The Echinacea/Sage lozenge contained 800 mg of hydroalcoholic extract of Echinacea purpurea (95% aerial parts and 5% root, Echinaforce®) and 378.5 mg of hydroalcoholic extract of Salvia officinalis leaves (drug extraction ratio 1:17).

Posologie

posologieOral route: root, aerial parts

posologie4000 mg

duration1 - days

formulationstandardized extract, dry extract


Synergies


Urinary tract infections
✪✪✪✪✪

Thanks to its immunostimulant and antibacterial properties, Echinacea is indicated for cystitis. ESCOP indicates it as an adjuvant and preventive therapy for recurrent infections of the urogenital tract.

Posologie

posologieOral route: root, aerial parts

posologie1500 - 2400 mg

formulationstandardized extract, dry extract


Gingivitis
✪✪✪✪✪

Preliminary clinical research shows that the use of a mouthwash containing echinacea, gotu kola and elderberry — 15 ml three times a day for 14 days — may prevent worsening of gingivitis compared with a placebo mouthwash, but it produces only minimal improvement in symptoms. The application of a periodontal patch containing echinacea, gotu kola and elderberry, either as a single dose or three times a day for 1 day then once a day for 2 days, appears to reduce some measures of inflammation and gingivitis at certain time points, but the effects are inconsistent.

Posologie

posologieBy mouth: root, aerial parts

posologie1500 - 2400 mg

duration14 days

formulationstandardized extract, dry extract


Synergies


Vaginal infections
✪✪✪✪✪

Clinical results on the prevention of female urogenital infections (fungal infections, candidiasis, herpes) appear mixed, despite promising laboratory results.nnA one-year double-blind, placebo-controlled trial studied the effects of an extract of the plant and root of E. purpurea (Echinaforce 800 mg twice daily) on the incidence and severity of genital herpes outbreaks in 50 patients. The study did not show a statistically significant advantage over placebo after 6 months of treatment.nn

Posologie

posologieOral route: root, aerial parts

posologie1600 - 2400 mg

formulationstandardized extract, dry extract


Skin healing
✪✪✪✪

On wounds, Echinacea extracts appear to act by inhibiting bacterial proliferation and promoting healing by stimulating collagen synthesis.nnThe EMA recognizes echinacea as a traditional herbal medicinal product for the treatment of minor superficial wounds but also to relieve spots and pimples caused by mild acne.nnThe Commission E approves the external use of the herb E. purpurea for poorly healing wounds and chronic ulcerations.nn

Posologie

posologieTopical route: root, aerial parts

posologie1500 - 2400 mg

formulationstandardized extract, dry extract


Properties


Immunostimulant

full-leaffull-leaffull-leaffull-leaf

The immunostimulatory properties of Echinacea appear to target both non-specific and specific immune function. The effects non-specific include increased macrophage proliferation and phagocytosis, as well as the secretion of interferon beta-2, tumor necrosis factor (TNF), and interleukin-1 (IL-1). The constituents of Echinacea thought to be involved in stimulating non-specific immune responses include high-molecular-weight polysaccharides such as heteroxylan and arabinogalactan, and lower-molecular-weight compounds such as alkylamides, chicoric acid, and echinacosides. Specific immune responses specific include activation of other components of the complement pathway and increased levels and activity of T lymphocytes, neutrophils, and natural killer (NK) cells. These effects may be due to the polysaccharides present in Echinacea.

Usages associés

Immune support, Common cold, Urinary tract infections, Respiratory infections

Antiviral

full-leaffull-leaffull-leafempty-leaf

Echinacea may have antiviral activity against influenza virus, vesicular stomatitis virus, and herpes simplex viruses (HSV-1 and HSV-2). Preliminary research using viruses from nasal secretions suggests that Echinacea purpurea may inhibit enveloped viruses such as coronaviruses, influenza viruses, parainfluenza viruses, respiratory syncytial viruses, and metapneumoviruses. Echinacea enhances resistance to upper respiratory tract infections caused by rhinoviruses. It also increases resistance to infections during treatments of cutaneous warts. Caffeic acid and chicoric acid have in vitro antiviral activity (lasting 24 to 48 hours).

Usages associés

Pharyngitis, Common cold, Respiratory infections

Antibacterial

full-leaffull-leafempty-leafempty-leaf

Echinacoside has a dose-dependent antibacterial inhibitory effect in vitro on the growth of certain microbes. This activity is more specific against Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, and the acne pathogen Propionibacterium acnes. An anti-adhesion activity to intestinal cells has also been observed against the pathogen Campylobacter jejuni, which is responsible for diarrhea.

Usages associés

Pharyngitis, urinary tract infections, gingivitis, skin healing

Antifungal

full-leaffull-leafempty-leafempty-leaf

Activity has been demonstrated against Candida albicans. It is corroborated by clinical results, particularly in the prevention of female urogenital infections. The polyacetylenic compounds of echinacea, including ketoalkenes and ketoalkynes, appear to be responsible for the antifungal activity, notably against the yeast Candida, including Candida albicans.nn

Usages associés

Vaginal infections

Anti-inflammatory

full-leaffull-leafempty-leafempty-leaf

Studies on echinacea have shown that alcohol extracts, from the three species (E. angustifolia, E. purpurea, and E. pallida), have anti-inflammatory properties. The active compounds responsible are:nn- Alkamides: inhibit the enzyme iNOS, which plays a role in the production of nitric oxide, a mediator of inflammation.nn- Caffeic Acid: increases the activity of arginase, an enzyme that helps reduce inflammation.nn- Alkylamides from the roots of E. purpurea: partially inhibit the enzymes COX-1 and COX-2, which are involved in the production of prostaglandins, compounds that contribute to inflammation and pain.nn


Wound healing

full-leafempty-leafempty-leafempty-leaf

Animal research suggests that Echinacea extracts can accelerate wound healing, improve epithelialization, and reduce inflammation. The constituent echinacoside appears to protect type III collagen from damage caused by free radicals, and may have activity against bacterial hyaluronidase, which is necessary for bacteria to spread through the skin and mucous membranes. Several uncontrolled clinical studies support the topical use of Echinacea to improve wound healing. A trial involving 4,598 people studied the effects of a preparation made from the juice of the aerial parts of E. purpurea on various wounds, burns, skin infections, and inflammatory skin conditions. Topical application of Echinacea produced an overall success rate of 85%, and the main component responsible for the improvement in wound healing appears to be echinacoside as noted above.

Usages associés

Skin healing


Safe dosage

Adults 18 years and older: 900 mg - 4000 mg (powder)

The recommended daily dose for an adult is 900 mg (equivalent raw plant material).nnIn studies, doses up to 4 g per day have been used.nnIn dry extract: 360 mg/daynnIn mother tincture (MT): 15 to 30 drops, 3 times per day.nn

Children aged 4 to 18 years: 900 mL - 2000 mL (powder)

Dosage according to the manufacturer; up to 2 g equivalent fresh plant per day in the acute phase.nnIn mother tincture (MT) from 12 years of age: 1 drop/kg/day, in three doses.nn


Interactions

Médicaments

Cyclophosphamide: moderate interaction

Echinacea appears to increase the immunostimulatory effect of low-dose cyclophosphamide, which may affect autoimmune diseases.

Cyclosporine: moderate interaction

Echinacea may inhibit the effect of cyclosporine.

Immunosuppressant: moderate interaction

Theoretically, echinacea may interfere with immunosuppressive therapy because of its immunostimulant activity. Immunosuppressant drugs include azathioprine, basiliximab, cyclosporine, daclizumab, muromonab-CD3, mycophenolate, tacrolimus, sirolimus, prednisone, and other corticosteroids.

Plantes ou autres actifs

Echinacea: moderate interaction

Echinacea appears to increase plasma caffeine concentrations by 30%. This is likely due to inhibition of cytochrome P450 1A2 (CYP1A2) by echinacea.


Precautions

Pregnant women: use with caution

There is preliminary evidence that women may safely use echinacea (Echinacea purpurea or Echinacea angustifolia) at doses of 250 mg to 1000 mg per day, or as tinctures up to 30 drops per day for 5 to 7 days during the first trimester of pregnancy without harming the fetus. nnPregnant women are advised to remain cautious and consult their physician.nn

Breastfeeding women: use with caution

No data available.nn

Autoimmune diseases: use with caution

Echinacea appears to stimulate immune function. Theoretically, it could exacerbate autoimmune diseases by increasing disease activity. Therefore, avoid or use echinacea with caution in people with autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, or other conditions.nn

Atopy: avoid

People with atopy (a genetic tendency toward allergic conditions) may be more likely to have an allergic reaction when taking echinacea. Case reports describe several instances of allergic reactions to echinacea consistent with IgE-mediated hypersensitivity. 34% of reactions were observed in patients with atopy.

Hemochromatosis: use with caution

In cases of hemochromatosis, echinacea use should be monitored.